Levotyroxin

Česká verzia

Authors: Jan Krátký
Authors place of work: 3. interní klinika 1. lékařské fakulty Univerzity Karlovy a VFN v Praze
Published in the journal: Vnitř Lék 2022; 68(1): 68-72
Category:

Summary

Levothyroxine is a synthetic levoisomer of thyroxine. Currently, it is one of the most commonly prescribed drugs worldwide. The main indication for levothyroxine treatment is hypothyroidism of any type. It is also used for suppression therapy in patients with thyroid cancer. The therapeutic dose depends on the residual thyroid secretion, the weight of the patient, and the purpose of the treatment. The initial dose typically ranges from 25 to 50 μg daily, with further adjustment according to the level of thyroid-stimulating hormone (TSH). Initial dose titration is not recommended during postoperative replacement therapy and in pregnant women with hypothyroidism.

Most of the plasma thyroxine is bound to transport proteins. However, only the free thyroxin is biologically active. Thyroxine is mainly a prohormone which is metabolized to the more active triiodothyronine.

Properly managed levothyroxine treatment is safe with minimal adverse effects. Palpitations and other symptoms of hyperthyroidism may occur with overdose. For proper absorption, levothyroxine should be taken on an empty stomach, separately from other medications, at least 30 minutes before breakfast. Absorption may be impaired by other medications, especially by those increasing the pH of gastric acid.

Keywords:

thyroid hormones – Hypothyroidism – levothyroxine

Zdroje

1. Vanderpump MP. The epidemiology of thyroid disease. Br Med Bull 2011;99:39-51

2. McLeod DS, Cooper DS. The incidence and prevalence of thyroid autoimmunity. Endocrine 2012;42:252-265.

3. Jonklaas J, Bianco AC, Cappola AR et al. Evidence‑Based Use of Levothyroxine/Liothyronine Combinations in Treating Hypothyroidism: A Consensus Document. Thyroid 2021;31:156-182.

4. Lindholm J, Laurberg P. Hypothyroidism and thyroid substitution: historical aspects. J Thyroid Res 2011;809341.

5. The Top 300 of 2019. Dostupné z<https://clincalc.com/DrugStats/Top300Drugs.aspx>

6. Fish LH, Schwartz HL, Cavanaugh J et all. Replacement dose, metabolism, and bioavailability of levothyroxine in the treatment of hypothyroidism. Role of triiodothyronine in pituitary feedback in humans. N Engl J Med 1987;31:764-770.

7. Pang X, Pu T, Xu L et all. Effect of l‑thyroxine administration before breakfast vs at bedtime on hypothyroidism: A meta‑analysis. Clin Endocrinol (Oxf) 2020;92:475-481.

8. Yen PM. Physiological and molecular basis of thyroid hormone action. Physiol Rev 2001;81:1097-1142.

9. Saravanan P, Siddique H, Simmons D J et al. Twenty‑four hour hormone profiles of TSH, Free T3 and free T4 in hypothyroid patients on combined T3/T4 therapy. Exp Clin Endocrinol Diabetes 2007;115:261-267.

10. Haugen BR, Alexander EK, Bible KC et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. 2016;Thyroid 26:1-133.

11. SPC přípravku Euthyrox dostupné z <https://www.sukl.cz/download/spc/SPC21491.pdf>

12. Santini F, Pinchera A, Marsili A et al. Lean body mass is a major determinant of levothyroxine dosage in the treatment of thyroid diseases. J Clin Endocrinol Metab 2005;90:124-127.

13. Papoian V, Ylli D, Felger EA et al. Evaluation of Thyroid Hormone Replacement Dosing in Overweight and Obese Patients After a Thyroidectomy. Thyroid 2019; 29: 1558-1562.

14. Stoll SJ, Pitt SC, Liu J et al. Thyroid hormone replacement after thyroid lobectomy. Surgery 2009;146:554-558.

15. Park S, Jeon MJ, Song E et al. Clinical Features of Early and Late Postoperative Hypothyroidism After Lobectomy. J Clin Endocrinol Metab 2017;102:1317-1324.

16. Doporučení pro prevenci, časný záchyt a léčbu tyreopatií v těhotenství 2018. Dostupné z <https://www.endokrinologie.cz/cs/doporuceni‑pro‑prevenci‑casny‑zachyt‑a-lecbu‑tyreopatii‑v-tehotenstvi-2018>

17. Alexander EK, Pearce EN, Brent GA et al. 2017 Guidelines of the American Thyroid Association for the Diagnosis and Management of Thyroid Disease During Pregnancy and the Postpartum. Thyroid 2017;27:315-389.

18. Dvorakova M. Levothyroxine therapy - factors influencing its outcome. Vnitr Lek 2016;62:50-55.

19. Vita R, Benvenga S. Tablet levothyroxine (L‑T4) malabsorption induced by proton pump inhibitor; a problem that was solved by switching to L‑T4 in soft gel capsule. Endocr Pract 2014;20:38-41.